Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. Supported by strong equity base, we are a rapidly growing company with a dynamic portfolio of technology at the
cutting edge of molecular diagnostics.
Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation, with responsibility for all Pall Corporation activities in the Asia Pacific region.
Andrew joined Pall in 2002 with the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was President. Andrew was appointed President and Chief Operating Officer of the US Filter Filtration and Separations Group in February 1998 after US Filter acquired Memtec Limited. Prior to his position at US Filter, Andrew was President and Chief Operating Officer of Memtec Limited from 1987 to 1997, and prior to that, at Baxter Healthcare Corporation where he was employed for 12 years in a number of positions. Andrew’s last assignment at Baxter Healthcare Corporation was as President of the corporation’s US based Medical Devices Division.
Andrew is Chairman of Universal Biosensors Inc., and a non executive Director of Cochlear Ltd and Vaxxas Pty Ltd.
Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors. Andrew was appointed as a Director of SpeeDx Pty Ltd in 2009.
John Klopp was Worldwide Vice President, Business Development, for Johnson & Johnson’s Diabetes Care Franchise when he retired in 2009. During his sixteen year career with J&J, he established several partnerships with other companies, led the acquisition of two publicly traded companies, and led several successful patent legal actions. The acquisitions represented over 90% of the Diabetes Care Franchise sales in 2009.
Prior to Johnson & Johnson, he was Manager of Licenses and Acquisitions for DuPont Medical Products Department. During his 28 year career with DuPont, he held positions of increasing responsibility in New Venture Development, turnarounds, partnership and joint venture development, and M&A. After the formation of a joint venture with Applied BioTechnology (Inc.), he was elected to the Board of ABT.
In 2010, he was appointed to the Research and Development Committee of the Juvenile Diabetes Research Foundation. He received B.S. and M.S. degrees in Chemical Engineering from Oklahoma State University. John was appointed as a Director of SpeeDx Pty Ltd in 2010.
After spending some time at Swiss pharmaceuticals company Novartis researching new HIV drugs (one of which has been approved and is in use today), Dr. Ogden went on to complete a PhD at University College London, investigating Kaposi’s sarcoma-associated herpesvirus. She then migrated to Australia and joined Johnson & Johnson as a molecular biologist, researching new drug targets in oncology.
Dr. Ogden embarked on a career change in 2003 and joined Platinum as an investment analyst. Her rich knowledge base in molecular biology and first-hand insights into the pharmaceutical and biotech industry give her a unique ability to delve deeply into the fundamentals of healthcare companies.
At Platinum Bianca manages the Platinum International Health Care Fund and leads the healthcare sector team.
Michael P. Rubin is the Founder and CEO of Northpond Ventures. Previously, Mike was the Co-founder and Managing Partner of Sands Capital Ventures, a global cross-industry venture capital business and affiliate of Sands Capital Management.
Under his leadership, Sands Capital Ventures invested in a plethora of leading businesses in multiple industries and geographies. Investments in biotechnology, life sciences, and diagnostics included: Acessa Health Inc.; Agilis Biotherapeutics, LLC (sold to PTC Therapeutics); Avitide, Inc.; Complete Genomics, Inc. (IPO; sold to BGI Genomics); Day Zero Diagnostics, Inc.; Dova Pharmaceuticals (IPO); Firefly BioWorks (sold to Abcam); Genometry, Inc.; Mitra Biotech; NanoView Biosciences; Quad Technologies (sold to Bio-Techne Corporation); and QVella Corporation.
Information technology investments included: Anaplan (IPO); AppDynamics (sold to Cisco); DocuSign (IPO); Health Catalyst (IPO); Kit Check, Inc.; Modernizing Medicine, Inc.; Mulesoft, LLC (sold to Salesforce); Scopely, Inc.; and Teckro, Inc. Investments in financial technology included: Funding Circle (IPO); LendingClub (IPO); Upgrade, Inc.; Neptune Financial Inc.; and Paydiant, Inc. (sold to PayPal).
Global internet franchises included: BigBasket; Blackbuck; and Souq (sold to Amazon).
Prior to joining Sands Capital Ventures, Mike became a board-certified physician and surgeon, completing his fellowship training at Harvard Medical School. Mike holds an MBA from University of Massachusetts Amherst; earned his medical doctorate at The University of Chicago; and holds a B.S. in electrical engineering from University of California, Los Angeles, Samueli School of Engineering, where he was the student graduation speaker. Mike is also a CFA charterholder.
Adam Wieschhaus is a Director at Northpond Ventures and leads the firm’s work in life science R&D solutions, molecular diagnostics, and environmental sciences. Previously, Adam was a Vice President at Cowen and Company, where he covered the life science tools and diagnostics space for six years.
Prior to Cowen, he conducted his postdoctoral studies at Tufts Medical School, where he developed and refined drug candidates across several therapeutic areas. He holds a Ph.D. from the University of Illinois College of Medicine, a B.S. in biochemistry and molecular biology from University of Georgia, and is a CFA charterholder.
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx employs a growing number of team members across our three offices in Sydney, Austin, and London. Follow us on LinkedIn for more information about SpeeDx careers.
Colin Denver is an experienced sales professional with nearly 20 years sales experience working in the Life Science and Diagnostic fields. He has experience in establishing new organisations having set up Bioline in Australia in 2004. Colin enjoyed continued growth while at Bioline with quarter on quarter growth achieved since inception. Colin went on to manage sales in Asia/Pacific for Meridian Bioscience (post Bioline acquisition) and drove consistent growth within the territory.
Colin started as Vice President of Sales and Marketing for SpeeDx, responsible for the promotion of all SpeeDx branded products as well as acquisition of new licensing and commercial agreements. He now holds the role of CEO, overseeing the expansion of SpeeDx as products are launched across Europe, United States and Australia/New Zealand. Colin holds a Bachelor of Science from Pepperdine University and a Post Graduate Diploma of Management from MGSM.
Elisa Mokany is a co-founder and the Chief Technology Officer at SpeeDx. In this role she leads the development of innovative diagnostic technologies and commercialization of infectious disease and antibiotic resistance tests. Elisa has over 20 years’ experience in medical research, she has worked for St Vincent’s hospital developing tests for the diagnosis of colorectal cancer and later at Johnson & Johnson Research (JJR) where she developed diagnostic tests for leukemia and was involved in the commercialisation of proprietary technology known as DzyNA PCR.
While at JJR, Elisa undertook studies towards her PhD, which involved co-invention of the novel nucleic acid technology, PlexZymes . Elisa is an inventor on 8 patents/patent applications involving nucleic acid analysis including the novel PlexPrime technology which has multiple applications in the in vitro diagnostic field. Elisa studied at the University of NSW, obtaining a BSc (Hons 1st Class) and later completed her PhD at JJR in conjunction with the School of Biotechnology and Biomolecular Science at the University of New South Wales.
Bhavin Raval has nearly 30 years of financial leadership experience across a broad range of industries including the last 18 years with Life Science and Biotech companies. He brings financial and executive leadership experience to SpeeDx in the areas of business operations, fiscal management and strategy, commercial partnering, M&A and integration activities, and private equity fundraising. His previous employers include Johnson & Johnson Research Pty Limited, Victor Chang Cardiac Research Institute and Calimmune Inc. He was a part of the senior management team of Calimmune Inc. that was acquired by CSL for a value of up to USD 416 M in August 2017. Bhavin is a Fellow Member of CPA Australia as well as a Fellow Member of the Governance Institute of Australia.
Adj/Professor Alison Todd co-founded SpeeDx in 2009 and is its Chief Scientific Officer. She is an elected Fellow of the Australian Academy of Technology and Engineering; and along with Dr Elisa Mokany, was the recipient of academy’s Clunies Ross Innovation Award in 2020 for “discovery, development, and adoption of a technology that has significantly improved societal or industry capabilities”.
Alison is a serial inventor with a portfolio of 18 patent families that comprises over 85 granted patents which protect SpeeDx ‘s IP including PlexZyme and PlexPrime. She is a pioneer in the field of personalised medicine, having pursued a career which has focused on developing and commercialising diagnostic tests for the tailoring and monitoring of therapy for patients with cancer or infectious diseases.
Prior to founding SpeeDx, Alison was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. She spent nearly 20 years within the pharmaceutical industry and was internationally recognised with the Johnson & Johnson Philip B. Hofmann Research Scientist Award for outstanding achievement in R&D.
Alison studied at the University of Sydney, obtaining a BSc (Hons 1st Class) before completing a PhD through the Faculty of Medicine in conjunction with Royal Prince Alfred Hospital. Alison maintains an active involvement within the academic community and is an Adjunct Professor at the University of New South Wales.